Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 7.32%, which has investors questioning if this is right time to buy.

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 13.42%, which has investors questioning if this is right time ...

Novo Nordisk will pay $75 million in up-front and near-term payments for Lexicon Pharmaceuticals’ LX9851, a small molecule the firm says it is developing for obesity and associated metabolic ...

SEONGNAM, South Korea I April 7, 2025 I ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, ...

RICHMOND, CA, USA I April 03, 2025 I Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”) ...

Approval was based on results from the Phase III ALIGN study, which demonstrated a significant reduction in proteinuria at 36 weeks in patients with primary immunoglobulin A nephropathy. Results from ...

At close: April 4 at 4:00:03 PM EDT ...